Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma

被引：0
|
作者：
Cerchione, Claudio [1 ]
Martinelli, Giovanni [2 ]
Nappi, Davide [3 ]
Pareto, Anna Emanuele [3 ]
Di Perna, Maria [3 ]
Ronconi, Sonia [4 ]
Pane, Fabrizio [3 ]
Catalano, Lucio [5 ]
机构：
[1] IRCCS, IRST, Meldola, FC, Italy
[2] IRCCS, Ist Sci Romagnolo Studio & Cura Tumori IRST, Hematol Unit, Meldola, FC, Italy
[3] AOU Federico II, Naples, Italy
[4] European Myeloma Network Italy, GIMEMA, Meldola, Italy
[5] AOU Federico II, GIMEMA, Naples, Italy
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期
关键词：
Heavily pretreated; Pomalidomide; Real-World Data;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SP-309
引用
收藏
页码：E359 / E359
页数：1
相关论文
共 50 条
  • [41] Pegfilgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Pomalidomide-Based Treatment
    Cerchione, Claudio
    Catalano, Lucio
    Nappi, Davide
    Pane, Fabrizio
    Martinelli, Giovanni
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S443 - S443
  • [42] Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis
    Sunami, Kazutaka
    Ikeda, Takashi
    Huang, Shang-Yi
    Wang, Ming-Chung
    Koh, Youngil
    Min, Chang Ki
    Yeh, Su-Peng
    Matsumoto, Morio
    Uchiyama, Michihiro
    Iyama, Satoshi
    Shimazaki, Chihiro
    Lee, Jae Hoon
    Kim, Kihyun
    Kaneko, Hitomi
    Kim, Jin Seok
    Lin, Tung-Liang
    Campana, Frank
    Tada, Keisuke
    Iida, Shinsuke
    Suzuki, Kenshi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (08): : E751 - E761
  • [43] Pomalidomide-Dexamethasone Effectiveness in t(11;14) Positive Relapsed Multiple Myeloma in Real-World Setting
    Karve, Sudeep
    Kumar, Shaji
    De La Calle, Veronica Gonzalez
    Mangiacavalli, Silvia
    Min, Chang-Ki
    Kastritis, Efstathios
    Esteves, Graca
    Delforge, Michel
    Escalante, Fernando
    Lu, Jin
    Liu, Yang
    Bittrich, Max
    Kyriakou, Charalampia
    Yee, Andrew J.
    Arriola, Emma
    Ross, Jeremy A.
    Manthena, Shivaji
    Durie, Brian G. M.
    BLOOD, 2021, 138 : 3803 - +
  • [44] Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting
    Hobbs, Miriam
    Paludo, Jonas
    Fonder, Amie
    Abeykoon, Jithma P.
    Gertz, Morie A.
    Rajkumar, S. Vincent
    Go, Ronald S.
    Buadi, Francis K.
    Lacy, Martha Q.
    Leung, Nelson
    Dispenzieri, Angela
    Gonsalves, Wilson I.
    Dingli, David
    Hwa, Yi L.
    Kourelis, Taxiarchis
    Kyle, Robert A.
    Kumar, Shaji
    Kapoor, Prashant
    BLOOD, 2016, 128 (22)
  • [45] 3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma
    Chim, Chor Sang
    Kumar, Shaji
    Wong, Vincent Kai Chung
    Ngai, Cheong
    Kwong, Yok Lam
    HEMATOLOGY, 2021, 26 (01) : 652 - 655
  • [46] Pomalidomide, bortezomib, and dexamethasone in lenalidomide-pretreated multiple myeloma: A subanalysis of OPTIMISMM by frailty.
    Rocafiguera, Albert Oriol
    Dimopoulos, Meletios A.
    Schjesvold, Fredrik
    Beksac, Meral
    Yagci, Munci
    Larocca, Alessandra
    Guo, Shien
    Mu, Yutian
    Hong, Kevin
    Dhanasiri, Sujith
    Richardson, Paul G.
    Weisel, Katja
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma
    Garderet, Laurent
    Kuhnowski, Frederique
    Berge, Benoit
    Roussel, Murielle
    Escoffre-Barbe, Martine
    Lafon, Ingrid
    Facon, Thierry
    Leleu, Xavier
    Karlin, Lionel
    Perrot, Aurore
    Moreau, Philippe
    Marit, Gerald
    Stoppa, Anne-Marie
    Royer, Bruno
    Chaleteix, Carine
    Tiab, Mourad
    Araujo, Carla
    Lenain, Pascal
    Macro, Margaret
    Voog, Eric
    Benboubker, Lofti
    Allangba, Olivier
    Jourdan, Eric
    Orsini-Piocelle, Frederique
    Brechignac, Sabine
    Eveillard, Jean-Richard
    Belhadj, Karim
    Wetterwald, Marc
    Pegourie, Brigitte
    Jaccard, Arnaud
    Eisenmann, Jean-Claude
    Glaisner, Sylvie
    Mohty, Mohamad
    Hulin, Cyrille
    Avet-Loiseau, Herve
    Mathiot, Claire
    Attal, Michel
    BLOOD, 2018, 132 (24) : 2555 - 2563
  • [48] Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
    Dimopoulos, Meletios Athanasios
    Beksac, Meral
    Pour, Ludek
    Delimpasi, Sosana
    Vorobyev, Vladimir
    Quach, Hang
    Spicka, Ivan
    Radocha, Jakub
    Robak, Pawel
    Kim, Kihyun
    Cavo, Michele
    Suzuki, Kazuhito
    Morris, Kristin
    Pompilus, Farrah
    Phillips-Jones, Amy
    Zhou, Xiaoou L.
    Fulci, Giulia
    Sule, Neal
    Kremer, Brandon E.
    Opalinska, Joanna
    Mateos, Maria-Victoria
    Trudel, Suzanne
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (05): : 408 - 421
  • [49] Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma
    Jimenez-Zepeda, Victor H.
    Reece, Donna E.
    Trudel, Suzanne
    Chen, Christine
    Tiedemann, Rodger
    Kukreti, Vishal
    LEUKEMIA & LYMPHOMA, 2013, 54 (03) : 555 - 560
  • [50] Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
    Dimopoulos, Meletios A.
    Dytfeld, Dominik
    Grosicki, Sebastian
    Moreau, Philippe
    Takezako, Naoki
    Hori, Mitsuo
    Leleu, Xavier
    LeBlanc, Richard
    Suzuki, Kenshi
    Raab, Marc S.
    Richardson, Paul G.
    McKiver, Mihaela Popa
    Jou, Ying-Ming
    Shelat, Suresh G.
    Robbins, Michael
    Rafferty, Brian
    San-Miguel, Jesus
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (19): : 1811 - 1822
12345